Danaher Corporation (DHR) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $185.78, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth.
Danaher is a global science and technology company with three segments—Biotechnology, Life Sciences, and Diagnostics—serving pharmaceutical, research, hospital, and industrial customers across ~50 countries with ~60,000 employees. Approximately 59% of 2025 sales were derived... Read more
Hold if already holding. Not a fresh buy at $185.78, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth. Chart setup: Death cross but MACD improving, RSI 67. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 41d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-10Recent Developments — Danaher Corporation
Latest news
- NEWS Danaher (DHR) Downgraded by Citigroup -- Price Target Lowered to $95 - GuruFocus — GuruFocus negative
- NEWS Danaher (DHR) Receives Buy Rating from Citi with $230 Price Targ - GuruFocus — GuruFocus positive
- NEWS Danaher Corporation Shs Cert Deposito Arg Repr 0.018518518 Sh Balance Sheet – BCBA:DHR.CI - TradingView — TradingView neutral
- NEWS Jefferies Financial Group Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price - MarketBeat — MarketBeat negative
- NEWS Sivik Global Healthcare LLC Trims Stock Holdings in Danaher Corporation $DHR - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicoutside the U.S.59%10-K Item 1A: 'In 2025 approximately 59% of our sales from continuing operations were derived from customers outside the U.S.'
- LOWGeographicChina11%10-K Item 1A: 'In 2025 we generated approximately 11% of our sales from continuing operations from China.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $185.78, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth. Chart setup: Death cross but MACD improving, RSI 67. Maintain position. Not compelling to add more. Target $219.85 (+18.3%), stop $175.38 (−5.9%), A.R:R 1.4:1. Score 5.2/10, moderate confidence.
Take-profit target: $219.85 (+18.4% upside). Target $219.85 (+18.3%), stop $175.38 (−5.9%), A.R:R 1.4:1. Stop-loss: $175.38.
Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend).
Danaher Corporation trades at a P/E of 36.5 (forward 20.7). TrendMatrix value score: 5.4/10. Verdict: Hold.
30 analysts cover DHR with a consensus score of 4.3/5. Average price target: $244.
What does Danaher Corporation do?Danaher is a global science and technology company with three segments—Biotechnology, Life Sciences, and...
Danaher is a global science and technology company with three segments—Biotechnology, Life Sciences, and Diagnostics—serving pharmaceutical, research, hospital, and industrial customers across ~50 countries with ~60,000 employees. Approximately 59% of 2025 sales were derived from outside the U.S., including ~11% from China, via a direct sales model with high recurring revenue from consumables and services.